The purpose of this document is to provide an update on the recently reported phenomenon of gadolinium deposition in the brain, and to
provide guidance to referring physicians ordering gadolinium-enhanced MRI studies at UW Health.
Patient information sheet about gadolinium-based contrast agentsFile: for-patients-gadolinium-contrast-for-magnetic-resonance-imaging.pdf
Extended table of clinically relevant information regarding gadolinium-based contrast agentsFile: mri-gadolinium-tables.pdf
Introduction to the calculations used to generate correct volume of any gadolinium-based contrast agentFile: how-to-calculate-volume-of-gadolinium-based-contrast-agents.pdf
charts showing standard and maximum dosages, and dosages based on weight for gadolinium-based contrast agentsFile: gadolinium-based-contrast-dosing-charts.pdf
The following memo provides an update on the UW-Madison Department of Radiology policy for scanning
patients who are breastfeeding
The following memo provides an interval update on the UW-Madison Department of Radiology policy for
scanning pregnant patients, including the use of gadolinium contrast agents, approved on 3/16/16 by the UW MRI Safety Committee.
This document describes modified screening procedures for mitigating the risk of nephrogenic
systemic fibrosis (NSF) in patients with renal failure undergoing gadolinium-enhanced MRI.